US Patent Issued to Bristol-Myers Squibb on May 6 for "Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-D3) pyridazine-3-carboxamide" (New Jersey Inventor)

ALEXANDRIA, Va., June 10 -- United States Patent no. 12,291,517, issued on May 6, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.).

"Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-D3) pyridazine-3-carboxamide" was invented by Daniel Richard Roberts (Robbinsville, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is crystalline Form B of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide. Form B is the HCl salt of a neat crystalline form. Characterization data for Form B are disclosed."

The patent was filed on Jan. 29, 2023, under Applica...